These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 20823670)

  • 1. [Development of delivery system of bisphosphonates for the treatment of osteoporosis].
    Katsumi H; Kusamori K; Sakane T; Yamamoto A
    Yakugaku Zasshi; 2010 Sep; 130(9):1129-33. PubMed ID: 20823670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates: therapeutics potential and recent advances in drug delivery.
    Fazil M; Baboota S; Sahni JK; Ameeduzzafar ; Ali J
    Drug Deliv; 2015 Jan; 22(1):1-9. PubMed ID: 24404750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
    Guay DR
    Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The successful development of bisphosphonates in the therapy of osteoporosis].
    Fassbender WJ; Stumpf UC; Kurth A
    Med Klin (Munich); 2006 Jun; 101 Suppl 1():6-14. PubMed ID: 16826363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates.
    McClung M
    Arq Bras Endocrinol Metabol; 2006 Aug; 50(4):735-44. PubMed ID: 17117298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption.
    Ezra A; Golomb G
    Adv Drug Deliv Rev; 2000 Aug; 42(3):175-95. PubMed ID: 10963835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bisphosphonate treatment of osteoporosis and other skeletal diseases].
    Syversen U; Halse JI
    Tidsskr Nor Laegeforen; 2011 Feb; 131(3):244-7. PubMed ID: 21304573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates: focus on inflammation and bone loss.
    Iannitti T; Rosini S; Lodi D; Frediani B; Rottigni V; Palmieri B
    Am J Ther; 2012 May; 19(3):228-46. PubMed ID: 22549638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New bone density conservation agents for osteoporosis under research and development: Ibandronate].
    Tanaka I; Hashimoto J; Oshima H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():426-32. PubMed ID: 18161144
    [No Abstract]   [Full Text] [Related]  

  • 10. Bisphosphonates, phossy jaw, and bisphosphonate-related osteonecrosis of the jaw.
    Lewis DM
    J Okla Dent Assoc; 2011; 102(5):36-9. PubMed ID: 21874699
    [No Abstract]   [Full Text] [Related]  

  • 11. [Development of novel delivery systems of drugs for the treatment of diabetes and osteoporosis].
    Yamamoto A
    Yakugaku Zasshi; 2010 Sep; 130(9):1113-4. PubMed ID: 20823667
    [No Abstract]   [Full Text] [Related]  

  • 12. Development of polyethylene glycol-conjugated alendronate, a novel nitrogen-containing bisphosphonate derivative: evaluation of absorption, safety, and effects after intrapulmonary administration in rats.
    Katsumi H; Takashima M; Sano J; Nishiyama K; Kitamura N; Sakane T; Hibi T; Yamamoto A
    J Pharm Sci; 2011 Sep; 100(9):3783-92. PubMed ID: 21567410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transplantable delivery systems for in situ controlled release of bisphosphonate in orthopedic therapy.
    Su K; Shi X; Varshney RR; Wang DA
    Expert Opin Drug Deliv; 2011 Jan; 8(1):113-26. PubMed ID: 21174607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Innovation of bisphosphonates for improvement of adherence.].
    Takeuchi Y
    Clin Calcium; 2017; 27(2):197-202. PubMed ID: 28123121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of bisphosphonates.
    Orozco C; Maalouf NM
    Rheum Dis Clin North Am; 2012 Nov; 38(4):681-705. PubMed ID: 23137577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term use of bisphosphonates in osteoporosis.
    Watts NB; Diab DL
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral bisphosphonates and osteonecrosis of the jaw.
    Wynn RL
    Gen Dent; 2007; 55(1):8-10. PubMed ID: 17333956
    [No Abstract]   [Full Text] [Related]  

  • 18. Fracture risk associated with chronic use of bisphosphonates: evidence today.
    Charopoulos I; Orme S; Giannoudis PV
    Expert Opin Drug Saf; 2011 Jan; 10(1):67-76. PubMed ID: 21121870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral delivery of zoledronic acid by non-covalent conjugation with lysine-deoxycholic acid: In vitro characterization and in vivo anti-osteoporotic efficacy in ovariectomized rats.
    Jeon OC; Seo DH; Kim HS; Byun Y; Park JW
    Eur J Pharm Sci; 2016 Jan; 82():1-10. PubMed ID: 26542347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bisphosphonate].
    Hagino H
    Nihon Rinsho; 2015 Oct; 73(10):1683-9. PubMed ID: 26529930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.